PUBLISHER: Lucintel | PRODUCT CODE: 1386206
PUBLISHER: Lucintel | PRODUCT CODE: 1386206
The future of the global rubella vaccine market looks promising with opportunities in the hospital, NGO, and pediatric clinic markets. The global rubella vaccine market is expected to reach an estimated $245.0 million by 2030 with a CAGR of 4.1% from 2024 to 2030. The major drivers for this market are growing demand for combination vaccines and rising adoption of rubella vaccination programs in developing countries.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global rubella vaccine by type, end use, and region.
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies rubella vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the rubella vaccine companies profiled in this report include-
Lucintel forecasts that measles-rubella vaccine is expected to witness highest growth over the forecast period due to it growing usage to protect against two highly contagious diseases including measles and rubella.
North America is expected to witness highest growth over the forecast perioddue to high vaccination coverage rates and presence of key manufacturer in the region.
Market Size Estimates: Rubella vaccine market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Rubella vaccine market size by type, end use, and region in terms of value ($M).
Regional Analysis: Rubella vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the rubella vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the rubella vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Answer: The global rubella vaccine market is expected to reach an estimated $245.0 million by 2030.
Answer: The global rubella vaccine market is expected to grow with a CAGR of 4.1% from 2024 to 2030.
Answer: The major drivers for this market are growing demand for combination vaccines and rising adoption of rubella vaccination programs in developing countries.
Answer: The future of the rubella vaccine market looks promising with opportunities in the hospital, NGO, and pediatric clinic markets.
Answer: Some of the key rubella vaccine companies are as follows:
Answer: Lucintel forecasts that measles-rubella vaccine is expected to witness highest growth over the forecast period due to it growing usage to protect against two highly contagious diseases including measles and rubella.
Answer: North America is expected to witness highest growth over the forecast perioddue to high vaccination coverage rates and presence of key manufacturer in the region.
Answer: Yes, Lucintel provides 10% customization without any additional cost.